Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
about
Allosteric antibody inhibition of human hepsin proteaseLaminin-332-beta1 integrin interactions negatively regulate invadopodiaProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model.ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cellsLaminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.Accurate molecular classification of cancer using simple rulesAssociation of hepsin gene variants with prostate cancer risk and prognosisDefining the role of laminin-332 in carcinoma.Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.An allosteric anti-hepsin antibody derived from a constrained phage display library.Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide librariesAging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.Integrin α3β1 regulates kidney collecting duct development via TRAF6-dependent K63-linked polyubiquitination of AktLow expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survivalMatrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior.Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.Membrane-anchored serine proteases in health and disease.Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4Components of cell-matrix linkage as potential new markers for prostate cancer.Integrin alpha6 maintains the structural integrity of the kidney collecting system.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP.A reporter mouse model for in vivo tracing and in vitro molecular studies of melanocytic lineage cells and their diseases.Skin basement membrane: the foundation of epidermal integrity--BM functions and diverse roles of bridging molecules nidogen and perlecan.Molecular and physiological mechanisms of membrane receptor systems functioning.The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.Mouse models of prostate cancer
P2860
Q27675904-631B0247-0192-48BC-A1FF-0892D9A461F2Q28571911-450E7C52-F885-404B-9445-2A61B3FB2532Q30409623-3A1CF671-9FC7-4A7E-97B7-EDFC37E8BFAEQ30432853-1272CB3E-7952-4538-A861-DA0868D735E9Q30497100-4C08974D-C176-4B8F-8F6D-AA2DFD9F55EEQ30540234-65CED743-E01C-4997-B342-8007CAE306EBQ33513762-B24BFA96-4AF0-4AD6-8465-193D7FFD29FCQ33872480-CCBA8839-CABB-4856-A6DE-BACDE1958AECQ33875126-CC5FE84A-8E07-486F-A57B-7722557FB577Q34078067-2C1AD252-A386-4494-B594-9A0A851748E6Q34132742-52B0E64B-61DD-46DA-BBBE-AB6471B0A6E2Q34165943-28E120FC-1058-4954-ADD8-84DE6560C317Q34507732-DA52DBE2-AAA6-4852-B614-65578D09E9BEQ34699785-BF3EE735-4FCD-4826-B9F8-1439E03503C5Q35095228-51AFECE1-C700-40AD-98FE-ADD22715B2D8Q35621960-DAACDF25-5436-4367-B25F-2E8FBA0BAD21Q35642678-0845751B-004E-4F12-BDF9-1617BC97FCACQ36566641-DC960B91-9442-42D1-B8C4-83C7A255C87CQ36618490-5D3B176F-B7B9-4CDB-83BA-EA652D371003Q36923138-4E766753-CD42-4FAD-9959-314A742104BEQ36946624-C16854E9-7B12-48FE-A118-D08022089E99Q36969010-20C31DCB-97C9-4B32-B747-F6B2CB4B55F4Q37204613-EA91B177-ADC6-425F-A077-34821625E583Q38161339-10F963B2-FBC7-487F-AF4E-5D8AE6B9F8FBQ39043889-36F52A23-BE7F-4B2C-ACA1-C6D120F05141Q39145828-D0119A45-3ECC-4E4E-BF5C-946A18B7BE98Q39376527-6893614B-E2CA-446B-92B0-B2CCC948E6D7Q41556263-A16FCE13-B264-4231-8094-D5FF8686D21CQ42124126-9BC037A9-F8C0-46AE-B160-CDC1216E094CQ42153161-EA2D7BA7-F31C-44F4-B7CA-C19FCE0B2BD6Q47168535-E4F14BC5-A195-44FA-97DB-9148CFDB3787Q47214955-C7EC60F7-4448-4CD8-97C4-34A641E5E488Q52661781-0B7141CD-A231-4E9F-BBD0-DD7D88BC332BQ55059193-35DE1136-5D47-4144-A5B8-B333EB656116Q58693513-8E6D397A-4664-4F7D-8864-190DCECAF07C
P2860
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Laminin-332 is a substrate for ...... h prostate cancer progression.
@en
Laminin-332 is a substrate for ...... h prostate cancer progression.
@nl
type
label
Laminin-332 is a substrate for ...... h prostate cancer progression.
@en
Laminin-332 is a substrate for ...... h prostate cancer progression.
@nl
prefLabel
Laminin-332 is a substrate for ...... h prostate cancer progression.
@en
Laminin-332 is a substrate for ...... h prostate cancer progression.
@nl
P2093
P2860
P356
P1476
Laminin-332 is a substrate for ...... h prostate cancer progression.
@en
P2093
Daniel Kirchhofer
Hironobu Yamashita
Manisha Tripathi
Rajkumar Ganesan
Srinivas Nandana
Vito Quaranta
P2860
P304
30576-30584
P356
10.1074/JBC.M802312200
P407
P577
2008-09-09T00:00:00Z